SI3621960T1 - Tienopiridini in benzotiofeni uporabni kot irak4 inhibitorji - Google Patents

Tienopiridini in benzotiofeni uporabni kot irak4 inhibitorji

Info

Publication number
SI3621960T1
SI3621960T1 SI201830426T SI201830426T SI3621960T1 SI 3621960 T1 SI3621960 T1 SI 3621960T1 SI 201830426 T SI201830426 T SI 201830426T SI 201830426 T SI201830426 T SI 201830426T SI 3621960 T1 SI3621960 T1 SI 3621960T1
Authority
SI
Slovenia
Prior art keywords
thienopyridines
benzothiophenes
useful
irak4 inhibitors
irak4
Prior art date
Application number
SI201830426T
Other languages
English (en)
Inventor
Saleem Ahmad
Ling Li
Lidet A. Negash
John Hynes
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI3621960T1 publication Critical patent/SI3621960T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
SI201830426T 2017-05-11 2018-05-10 Tienopiridini in benzotiofeni uporabni kot irak4 inhibitorji SI3621960T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504956P 2017-05-11 2017-05-11
EP18727589.6A EP3621960B1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors
PCT/US2018/031945 WO2018209012A1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors

Publications (1)

Publication Number Publication Date
SI3621960T1 true SI3621960T1 (sl) 2021-11-30

Family

ID=62245511

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830426T SI3621960T1 (sl) 2017-05-11 2018-05-10 Tienopiridini in benzotiofeni uporabni kot irak4 inhibitorji

Country Status (27)

Country Link
US (1) US10829496B2 (sl)
EP (1) EP3621960B1 (sl)
JP (1) JP7154229B2 (sl)
KR (1) KR102604900B1 (sl)
CN (1) CN110612298B (sl)
AR (1) AR111689A1 (sl)
AU (1) AU2018265130B2 (sl)
BR (1) BR112019023290A2 (sl)
CA (1) CA3062602A1 (sl)
CL (1) CL2019003198A1 (sl)
CO (1) CO2019012494A2 (sl)
CY (1) CY1124552T1 (sl)
DK (1) DK3621960T3 (sl)
EA (1) EA039189B1 (sl)
ES (1) ES2889926T3 (sl)
HR (1) HRP20211583T1 (sl)
HU (1) HUE056493T2 (sl)
IL (1) IL270494B (sl)
LT (1) LT3621960T (sl)
MX (1) MX2019012929A (sl)
PE (1) PE20191817A1 (sl)
PL (1) PL3621960T3 (sl)
PT (1) PT3621960T (sl)
RS (1) RS62430B1 (sl)
SI (1) SI3621960T1 (sl)
TW (1) TW201900640A (sl)
WO (1) WO2018209012A1 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL273432B (en) 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
AU2018396142A1 (en) 2017-12-26 2020-07-16 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
JP2022516401A (ja) 2018-11-30 2022-02-28 カイメラ セラピューティクス, インコーポレイテッド Irak分解剤およびそれらの使用
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
EP4004000A1 (en) * 2019-07-23 2022-06-01 Bristol-Myers Squibb Company Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
BR112022011651A2 (pt) 2019-12-17 2022-08-23 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
CN111285844B (zh) * 2020-02-24 2022-08-12 河南师范大学 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
EP1399440B1 (en) 2001-06-15 2009-06-03 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
US20070043049A1 (en) 2003-07-10 2007-02-22 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
CN101171052A (zh) 2005-03-09 2008-04-30 先灵公司 抑制ksp驱动蛋白活性的化合物
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
AR059246A1 (es) 2006-01-30 2008-03-19 Array Biopharma Inc Compuestos heterobiciclicos de tiofeno y metodos de uso
US8273759B2 (en) 2007-06-08 2012-09-25 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
JP5254693B2 (ja) 2008-07-30 2013-08-07 三菱重工業株式会社 Ni基合金用溶接材料
EP2361902A4 (en) 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
EP2380877A4 (en) 2008-11-28 2012-06-27 Kowa Co PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
US8586751B2 (en) 2009-06-12 2013-11-19 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
US8614234B2 (en) 2009-09-03 2013-12-24 Allergan, Inc. Compounds as tyrosine kinase modulators
JP5770198B2 (ja) 2009-10-30 2015-08-26 ヤンセン ファーマシューティカ エヌ.ベー. オピオイド受容体調節因子としてのフェノキシ置換ピリミジン
EP2532656A1 (en) 2010-02-01 2012-12-12 Nippon Chemiphar Co., Ltd. Gpr119 agonist
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
CN103619854A (zh) 2011-04-29 2014-03-05 西奈山伊坎医学院 激酶抑制剂
CN104254533B (zh) 2012-01-13 2017-09-08 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
JP6096807B2 (ja) 2012-01-13 2017-03-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キナーゼ阻害剤として有用なトリアゾリル置換されたピリジル化合物
CN104159896B (zh) * 2012-01-13 2017-05-24 百时美施贵宝公司 用作激酶抑制剂的杂环取代的吡啶基化合物
SG11201503396UA (en) 2012-11-08 2015-05-28 Bristol Myers Squibb Co ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES
CN104781254B (zh) 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经杂芳基取代的吡啶基化合物
EP2922840B1 (en) 2012-11-08 2016-12-21 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物
MA52856B1 (fr) 2014-04-04 2022-03-31 Pfizer Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
WO2016144844A1 (en) * 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Carboxamide inhibitors of irak4 activity
US10040802B2 (en) * 2015-03-12 2018-08-07 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of IRAK4 activity
UY36747A (es) 2015-06-24 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
WO2016210034A1 (en) 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
JP6804524B2 (ja) 2015-08-27 2020-12-23 ファイザー・インク Irak4モジュレーターとしての二環式縮合ヘテロアリールまたはアリール化合物

Also Published As

Publication number Publication date
JP2020519596A (ja) 2020-07-02
US20200062777A1 (en) 2020-02-27
MX2019012929A (es) 2020-01-14
LT3621960T (lt) 2021-10-11
DK3621960T3 (da) 2021-09-27
CY1124552T1 (el) 2022-07-22
CN110612298A (zh) 2019-12-24
PE20191817A1 (es) 2019-12-27
CO2019012494A2 (es) 2020-01-17
IL270494B (en) 2022-04-01
RS62430B1 (sr) 2021-11-30
ES2889926T3 (es) 2022-01-14
EA201992674A1 (ru) 2020-04-06
US10829496B2 (en) 2020-11-10
WO2018209012A1 (en) 2018-11-15
EP3621960A1 (en) 2020-03-18
EP3621960B1 (en) 2021-08-04
AU2018265130A1 (en) 2020-01-02
KR102604900B1 (ko) 2023-11-21
PT3621960T (pt) 2021-09-16
AR111689A1 (es) 2019-08-07
CL2019003198A1 (es) 2020-03-20
BR112019023290A2 (pt) 2020-06-16
KR20200004871A (ko) 2020-01-14
PL3621960T3 (pl) 2021-11-08
AU2018265130B2 (en) 2022-03-24
HUE056493T2 (hu) 2022-02-28
JP7154229B2 (ja) 2022-10-17
CN110612298B (zh) 2023-05-05
CA3062602A1 (en) 2018-11-15
EA039189B1 (ru) 2021-12-15
TW201900640A (zh) 2019-01-01
HRP20211583T1 (hr) 2022-01-07

Similar Documents

Publication Publication Date Title
IL270494B (en) Thienopyridines and benzothiophenase are useful as irak4 inhibitors
IL269711B (en) ask1 inhibitory compounds and uses thereof
EP3268003A4 (en) Thienopyrazine inhibitors of irak4 activity
IL269196A (en) New inhibitors
EP3283488A4 (en) Heterocycles useful as ido and tdo inhibitors
FI3672976T3 (fi) Bcl-2-inhibiittoreita
EP3336091A4 (en) IRAQ4 INHIBITOR AND ITS USE
SG11202003790PA (en) Composition and method
SI3621694T1 (sl) Zaviralci lrrc33 in njihove uporabe
IL274425A (en) Pyrrolopyrazine derivatives as alpha five integrin inhibitors
EP3336090A4 (en) INHIBITOR OF IRAQ4 AND ITS USE
ZA201907136B (en) Ip6k inhibitors
HUE052351T2 (hu) NAP I-IIB inhibitor kondenzált tiofén-származékok
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL263949A (en) Complement inhibitors and their uses
IL275935A (en) Its use and its derivative
IL274550A (en) Dopamine-B-hydroxylase inhibitors
EP3704104A4 (en) IRAK4 INHIBITORS AND THEIR USES
PT3725791T (pt) Sal que serve como inibidor de akt e seu cristal
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
IL281216A (en) Inhibitors of glutaminyl cyclase
ZA201904187B (en) Method and composition
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201714238D0 (en) Composition and method